|
1
|
Corso S, Ghiso E, Cepero V, Sierra JR,
Migliore C, Bertotti A, Trusolino L, Comoglio PM and Giordano S:
Activation of HER family members in gastric carcinoma cells
mediates resistance to MET inhibition. Mol Cancer. 9:1212010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Solit DB, Basso AD, Olshen AB, Scher HI
and Rosen N: Inhibition of heat shock protein 90 function
down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer
Res. 63:2139–2144. 2003.PubMed/NCBI
|
|
3
|
Kazlauskas A and Cooper JA:
Phosphorylation of the PDGF receptor beta subunit creates a tight
binding site for phosphatidylinositol 3 kinase. EMBO J.
9:3279–3286. 1990.PubMed/NCBI
|
|
4
|
Chiang EP, Tsai SY, Kuo YH, Pai MH, Chiu
HL, Rodriguez RL and Tang FY: Caffeic acid derivatives inhibit the
growth of colon cancer: Involvement of the PI3-K/Akt and AMPK
signaling pathways. PLoS One. 9:e996312014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gustin JP, Karakas B, Weiss MB, Abukhdeir
AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi
Y, et al: Knockin of mutant PIK3CA activates multiple oncogenic
pathways. Proc Natl Acad Sci USA. 106:2835–2840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kang S, Bader AG and Vogt PK:
Phosphatidylinositol 3-kinase mutations identified in human cancer
are oncogenic. Proc Natl Acad Sci USA. 102:802–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang QS, Papanikolaou A, Sabourin CL and
Rosenberg DW: Altered expression of cyclin D1 and cyclin-dependent
kinase 4 in azoxymethane-induced mouse colon tumorigenesis.
Carcinogenesis. 19:2001–2006. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Halilovic E, She QB, Ye Q, Pagliarini R,
Sellers WR, Solit DB and Rosen N: PIK3CA mutation uncouples tumor
growth and cyclin D1 regulation from MEK/ERK and mutant KRAS
signaling. Cancer Res. 70:6804–6814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dienstmann R, Rodon J, Serra V and
Tabernero J: Picking the point of inhibition: A comparative review
of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 13:1021–1031.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Chen J, Wang L, Huang Y, Leng Y
and Wang G: Fangchinoline induces G0/G1 arrest by modulating the
expression of CDKN1A and CCND2 in K562 human chronic myelogenous
leukemia cells. Exp Ther Med. 5:1105–1112. 2013.PubMed/NCBI
|
|
11
|
Nakamura K, Tsuchiya S, Sugimoto Y,
Sugimura Y and Yamada Y: Histamine release inhibition activity of
bisbenzylisoquinoline alkaloids. Planta Med. 58:505–508. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim HS, Zhang YH, Oh KW and Ahn HY:
Vasodilating and hypotensive effects of fangchinoline and
tetrandrine on the rat aorta and the stroke-prone spontaneously
hypertensive rat. J Ethnopharmacol. 58:117–123. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hristova M and Istatkova R:
Complement-mediated antiinflammatory effect of
bisbenzylisoquinoline alkaloid fangchinoline. Phytomedicine.
6:357–362. 1999. View Article : Google Scholar
|
|
14
|
Choi HS, Kim HS, Min KR, Kim Y, Lim HK,
Chang YK and Chung MW: Anti-inflammatory effects of fangchinoline
and tetrandrine. J Ethnopharmacol. 69:173–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen YC, Chou CJ, Chiou WF and Chen CF:
Anti-inflammatory effects of the partially purified extract of
radix Stephaniae tetrandrae: Comparative studies of its active
principles tetrandrine and fangchinoline on human polymorphonuclear
leukocyte functions. Mol Pharmacol. 60:1083–1090. 2001.PubMed/NCBI
|
|
16
|
Kim HS, Zhang YH and Yun YP: Effects of
tetrandrine and fangchinoline on experimental thrombosis in mice
and human platelet aggregation. Planta Med. 65:135–138. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsutsumi T, Kobayashi S, Liu YY and
Kontani H: Antihyperglycemic effect of fangchinoline isolated from
Stephania tetrandra Radix in streptozotocin-diabetic mice. Biol
Pharm Bull. 26:313–317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma W, Nomura M, Takahashi-Nishioka T and
Kobayashi S: Combined effects of fangchinoline from Stephania
tetrandra Radix and formononetin and calycosin from Astragalus
membranaceus Radix on hyperglycemia and hypoinsulinemia in
streptozotocin-diabetic mice. Biol Pharm Bull. 30:2079–2083. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin TY, Lu CW, Tien LT, Chuang SH, Wang
YR, Chang WH and Wang SJ: Fangchinoline inhibits glutamate release
from rat cerebral cortex nerve terminals (synaptosomes). Neurochem
Int. 54:506–512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gülçin I, Elias R, Gepdiremen A, Chea A
and Topal F: Antioxidant activity of bisbenzylisoquinoline
alkaloids from Stephania rotunda: Cepharanthine and fangchinoline.
J Enzyme Inhib Med Chem. 25:44–53. 2010. View Article : Google Scholar
|
|
21
|
Sekiya N, Hikiami H, Yokoyama K, Kouta K,
Sakakibara I, Shimada Y and Terasawa K: Inhibitory effects of
Stephania tetrandra S. Moore on free radical-induced lysis of rat
red blood cells. Biol Pharm Bull. 28:667–670. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang YH, Fang LH and Ku BS: Fangchinoline
inhibits rat aortic vascular smooth muscle cell proliferation and
cell cycle progression through inhibition of ERK1/2 activation and
c-fos expression. Biochem Pharmacol. 66:1853–1860. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng LH, Zhang H, Hayward L, Takemura H,
Shao RG and Pommier Y: Tetrandrine induces early G1 arrest in human
colon carcinoma cells by down-regulating the activity and inducing
the degradation of G1-S-specific cyclin-dependent kinases and by
inducing p53 and p21Cip1. Cancer Res. 64:9086–9092. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun X, Xu R, Deng Y, Cheng H, Ma J, Ji J
and Zhou Y: Effects of tetrandrine on apoptosis and
radiosensitivity of nasopharyngeal carcinoma cell line CNE. Acta
Biochim Biophys Sin (Shanghai). 39:869–878. 2007. View Article : Google Scholar
|
|
25
|
Wang N, Pan W, Zhu M, Zhang M, Hao X,
Liang G and Feng Y: Fangchinoline induces autophagic cell death via
p53/sestrin2/AMPK signalling in human hepatocellular carcinoma
cells. Br J Pharmacol. 164(2b): 731–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang CD, Yuan CF, Bu YQ, Wu XM, Wan JY,
Zhang L, Hu N, Liu XJ, Zu Y, Liu GL, et al: Fangchinoline inhibits
cell proliferation via Akt/GSK-3beta/cyclin D1 signaling and
induces apoptosis in MDA-MB-231 breast cancer cells. Asian Pac J
Cancer Prev. 15:769–773. 2014. View Article : Google Scholar
|
|
27
|
Xing Z, Zhang Y, Zhang X, Yang Y, Ma Y and
Pang D: Fangchinoline induces G1 arrest in breast cancer cells
through cell-cycle regulation. Phytother Res. 27:1790–1794. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xing ZB, Yao L, Zhang GQ, Zhang XY, Zhang
YX and Pang D: Fangchinoline inhibits breast adenocarcinoma
proliferation by inducing apoptosis. Chem Pharm Bull (Tokyo).
59:1476–1480. 2011. View Article : Google Scholar
|
|
29
|
Sun HW, Tong SL, He J, Wang Q, Zou L, Ma
SJ, Tan HY, Luo JF and Wu HX: RhoA and RhoC -siRNA inhibit the
proliferation and invasiveness activity of human gastric carcinoma
by Rho/PI3K/Akt pathway. World J Gastroenterol. 13:3517–3522. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schnell O, Krebs B, Wagner E, Romagna A,
Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, et al:
Expression of integrin alphavbeta3 in gliomas correlates with tumor
grade and is not restricted to tumor vasculature. Brain Pathol.
18:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raynaud FI, Eccles S, Clarke PA, Hayes A,
Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, et
al: Pharmacologic characterization of a potent inhibitor of class I
phosphatidylinositide 3-kinases. Cancer Res. 67:5840–5850. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leung E, Kim JE, Rewcastle GW, Finlay GJ
and Baguley BC: Comparison of the effects of the PI3K/mTOR
inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast
cancer cells. Cancer Biol Ther. 11:938–946. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pavletich NP: Mechanisms of
cyclin-dependent kinase regulation: Structures of Cdks, their
cyclin activators, and Cip and INK4 inhibitors. J Mol Biol.
287:821–828. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
35
|
Prasad R, Vaid M and Katiyar SK: Grape
proanthocyanidin inhibit pancreatic cancer cell growth in vitro and
in vivo through induction of apoptosis and by targeting the
PI3K/Akt pathway. PLoS One. 7:e430642012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gan B, Yoo Y and Guan JL: Association of
focal adhesion kinase with tuberous sclerosis complex 2 in the
regulation of s6 kinase activation and cell growth. J Biol Chem.
281:37321–37329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schlaepfer DD and Hunter T: Signal
transduction from the extracellular matrix - a role for the focal
adhesion protein-tyrosine kinase FAK. Cell Struct Funct.
21:445–450. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao J and Guan JL: Signal transduction by
focal adhesion kinase in cancer. Cancer Metastasis Rev. 28:35–49.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hara T, Miyazaki H, Lee A, Tran CP and
Reiter RE: Androgen receptor and invasion in prostate cancer.
Cancer Res. 68:1128–1135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Libra M, Scalisi A, Vella N, Clementi S,
Sorio R, Stivala F, Spandidos DA and Mazzarino C: Uterine cervical
carcinoma: Role of matrix metalloproteinases (Review). Int J Oncol.
34:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kanaki T, Bujo H, Mori S, Yanjuan Z,
Takahashi K, Yokote K, Morisaki N and Saito Y: Functional analysis
of aortic endothelial cells expressing mutant PDGF receptors with
respect to expression of matrix metalloproteinase-3. Biochem
Biophys Res Commun. 294:231–237. 2002. View Article : Google Scholar : PubMed/NCBI
|
